Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML
These findings suggest that Visomitin exerts potent anti-leukemic effects by simultaneously promoting differentiation and apoptosis through ROS-mediated SYK inhibition. The selective activity against malignant cells and favorable <i>in vivo</i> efficacy suggest that Visomitin is a potential therapeutic agent for AML.
Authors
- Byeol-Eun Jeon
- Chan-Seong Kwon
- Sangwoo Kim (ORCID: https://orcid.org/0000-0002-6646-9376)
- youngseuk Cho
- Ho-Jin Shin
- Ji-Eun Lee
- Su-Ji Lee
- Youngmi Jung
Institutions
- Pusan National University Hospital (KR)
- Pusan National University (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.3389/fphar.2026.1741351
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation